GentiBio
Mirna is excited to bring her 15 years of drug development experience to GentiBio in the Sr. Director, Head of Process and Analytical Development role. Prior to joining GentiBio, Mirna contributed to the development of CAR-T cell therapies targeting blood cancers at Juno Therapeutics/Bristol Myers Squibb in process development and CMC team leadership roles. Before transitioning to cell therapy development, Mirna was a process development and technology lead on therapeutic monoclonal antibody programs at Amgen. Mirna holds a B.S. in Chemical Engineering and Ph.D. in Bioengineering from University of Washington.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.